Revenue segments as reported by the company.

Life Sciences and Applied Markets Group

Diagnostics and Genomics Group

Agilent CrossLab Group

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Agilent Technologies

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Agilent Technologies posts strong Q1 earnings, eyes PFAS testing and CRISPR expansion

Agilent Technologies delivered robust Q1 results, raised full-year guidance, and remains confident in its growth drivers. Despite challenges in the genomics market and uncertainties ahead, the company is strategically positioned to capitalize on opportunities and drive continued success.

Agilent reports strong Q2 earnings but revises down second-half forecast

Agilent Technologies delivered strong Q2 results but revised down second-half forecasts due to economic uncertainties. The company remains focused on driving margin expansion, cost efficiencies, and customer service excellence. Challenges from macroeconomic factors and market dynamics are being addressed with a strategic outlook for long-term growth.

Agilent Technologies faces China revenue challenges but eyes growth opportunities

Agilent Technologies faces revenue challenges in China but sees growth opportunities in companion diagnostics and liquid biopsy markets. The company remains confident in its ability to drive earnings growth despite recent setbacks.

Agilent reports mixed Q4 results, eyes steady recovery in 2024

Agilent Technologies reported mixed Q4 results with revenue decline but exceeded EPS guidance. While facing challenges in China and certain segments, the company anticipates slow but steady recovery for FY 2024. Agilent is focusing on cost-saving measures, pricing trends, and investments in growth areas like genomics and environmental solutions.

Agilent reports Q1 revenue decline, eyes global growth opportunities

Agilent Technologies' Q1 performance showed revenue decline but with strengths in certain segments like ACG and consumables. Challenges include revenue declines in DGG and LSAG impacting margins. Opportunities lie in global growth prospects and potential market surprises.

Agilent Technologies faces revenue decline but eyes growth opportunities ahead

Agilent Technologies navigated a challenging market in Q2 2024 with revenue declines across all end markets. The company remains focused on customer-centric strategies, cost optimization, and growth investments while addressing visibility challenges and exploring opportunities in high-growth segments.

Agilent reports Q3 earnings beat, eyes growth through acquisitions

Agilent Technologies delivered a solid performance in Q3 2024, exceeding earnings per share guidance and raising revenue and EPS midpoint guidance.
While facing revenue decline, the company's strategic investments and acquisitions signal a focus on growth and innovation.
Challenges include market dynamics and integration risks, but opportunities exist in leveraging digital initiatives and financial strength for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Agilent (A) reported earnings 30 days ago. What's next for the stock?

Why Is Agilent (A) Down 19.3% Since Last Earnings Report?

Automatic Data Processing

Lamar Advertising

Saratoga Investment

VMware

West Bancorp

According to the GuruFocus All-In-One Screener, a Premium feature, the following companies were trading with low price-sales ratios as of March 3.

6 Guru Stocks Trading With Low Price-Sales Ratios

Agilent (A) reports solid fiscal first-quarter results driven by strength in all revenue segments.

Agilent (A) Q1 Earnings In Line With Estimates, Revenues Top

Agilent Technologies, Inc. (A) CEO Mike McMullen on Q1 2020 Results - Earnings Call Transcript

Agilent Techonologies Inc. A, -1.20% shares declined in the extended session Tuesday after the lab instruments maker said its outlook would be impacted by the novel coronavirus.

Agilent stock slips as coronavirus dings outlook

Agilent's (A) leadership position and strength in revenue segments are likely to reflect on fiscal first-quarter results.

Agilent (A) Gears Up for Q1 Earnings: What's in the Cards?

Agile Therapeutics Inc (NASDAQ: AGRX) shares are advancing Tuesday after the company announced clinching of a term loan facility.

Agile Finalizes $35M Term Loan Facility As Twirla PDUFA Date Looms

Twist Bioscience is enjoying a stock lift after announcing the settlement of a trade secret lawsuit filed by Agilent Technologies. Investors may feel more confident in Twist’s prospects in silicon-based DNA manufacturing  - a big component of the synthetic biology industry.

Twist Bioscience Market Cap Up 18% To $1.1B On Settlement Of Legal Dispute With Agilent

Twist Bioscience Corp

Twist will pay Agilent $22.5 million and receive a license to aspects of its technology.

Twist Biosciences and Agilent Settle Dispute, Avoid Costly Trial

Chipotle

Starbucks

Investor William Ackman updated clients on his portfolio on Wednesday saying his Pershing Square Capital Management exited its Starbucks Corp.  position as future growth looks less robust but will stick with last year's biggest winner, Chipotle Mexican Grill Inc.

Ackman's Pershing Square exits Starbucks, sticks by Chipotle, sees gains at Agilent

Cisco Systems

Alphabet

Expeditors International of Washington

Gilead Sciences

W.W. Grainger

Charles Schwab

The Parnassus Endeavor Fund (Trades, Portfolio), which is part of Jerome Dodson's firm that provides responsible investment funds to the public, acquired shares of the following stocks during the fourth quarter.

Parnassus Endeavor Fund Adds to Cisco, Alphabet and more

Why Is Agilent (A) Up 5.4% Since Last Earnings Report?

Pershing Square Capital Management, the activist firm founded by Bill Ackman (Trades, Portfolio), disclosed this week it established a new holding in Agilent Technologies Inc.

Bill Ackman’s Pershing Square Packs Into Agilent

Agilent Technologies gain after-hours trading after hedge fund investor Bill Ackman revealed he has taken a stake in the company.

Agilent shares rise after Bill Ackman stake revealed

Agilent (A) reports solid fiscal fourth-quarter results driven by strength in all its revenue segments.

Agilent (A) Earnings and Revenues Surpass Estimates in Q4

Agilent Technologies, Inc. (A) CEO Mike McMullen on Q4 2019 Results - Earnings Call Transcript

Agilent (A) delivered earnings and revenue surprises of 3.49% and 2.98%, respectively, for the quarter ended October 2019. Do the numbers hold clues to what lies ahead for the stock?

Agilent Technologies (A) Surpasses Q4 Earnings and Revenue Estimates

Agilent (A) earnings for the research, development and manufacturing company's fiscal fourth quarter of 2019 have A stock down on Monday.
The post Agilent Earnings: A Stock Drops 3% Despite Q4 Beat appeared first on InvestorPlace.

Agilent Earnings: A Stock Drops 3% Despite Q4 Beat

Agilent (A) hikes dividend to 18 cents per share in a bid to reward its shareholders.

Agilent (A) Hikes Quarterly Dividend to Reward Shareholders

Agilent Technologies Inc. A, -0.97% said late Wednesday its board of directors has increased the company's quarterly dividend to 18 cents a share, a 10% increase over the previous quarter's dividend.

Agilent raises dividend by 10%

Agilent's (A) leadership position and strength in revenue segments are likely to reflect on fiscal fourth-quarter results.

Agilent (A) Gears Up for Q4 Earnings: What's in the Cards?

Brunswick

Entegris

Here are three stock picks from one of the best fund managers in the world.

3 Stocks This Top Wall Street Pro Is Buying Right Now

Agilent Technologies (A) opens a new facility in U.K. for research and development in the field of spectroscopy.

Agilent Boosts Spectroscopy Share With New Facility in UK

Naspers Ltd

UniFirst

According to Benjamin Graham's financial strength criterion, if investors screen for stocks whose current ratio is more than 2 and has higher working capital than long-term debt, they should find high-quality companies.

Consider These Stocks to Enhance the Quality of Your Portfolio

Danaher

General Electric

Thermo Fisher Scientific

Increased use of reagents in the field of research, bioscience and genetics is pushing the biotechnology reagents market higher.

News for Agilent Technologies Stock (A)